Cargando…

Multicenter Study of Trimethoprim/Sulfamethoxazole-Related Hepatotoxicity: Incidence and Associated Factors among HIV-Infected Patients Treated for Pneumocystis jirovecii Pneumonia

The incidence of hepatotoxicity related to trimethoprim/sulfamethoxazole (TMP/SMX) administered at a therapeutic dose may vary among study populations of different ethnicities and hepatotoxic metabolites of TMP/SMX may be decreased by drug-drug interaction with fluconazole. We aimed to investigate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jen-Jia, Huang, Chung-Hao, Liu, Chun-Eng, Tang, Hung-Jen, Yang, Chia-Jui, Lee, Yi-Chien, Lee, Kuan-Yeh, Tsai, Mao-Song, Lin, Shu-Wen, Chen, Yen-Hsu, Lu, Po-Liang, Hung, Chien-Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153565/ https://www.ncbi.nlm.nih.gov/pubmed/25184238 http://dx.doi.org/10.1371/journal.pone.0106141

Ejemplares similares

A Case of Pneumonia Caused by Pneumocystis jirovecii Resistant to Trimethoprim-Sulfamethoxazole
por: Lee, Sang Min, et al.
Publicado: (2015)

Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients
por: Goto, Norihiko, et al.
Publicado: (2017)

Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
por: Prasad, G. V. Ramesh, et al.
Publicado: (2019)

Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients
por: Ji, Jianlei, et al.
Publicado: (2021)

Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review
por: Haseeb, Abdul, et al.
Publicado: (2022)

Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies
por: Hammarström, Helena, et al.
Publicado: (2022)

Impact of an Intravenous Trimethoprim/Sulfamethoxazole Shortage on Treatment Outcomes Among HIV-Infected Patients with Pneumocystis jirovecii Pneumonia
por: Dilworth, Thomas J., et al.
Publicado: (2014)

807. Trimethoprim/Sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in B-cell lymphoma: A multicenter randomized double-blinded placebo-controlled trial
por: Angsutararux, Taksaon, et al.
Publicado: (2023)

Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality
por: Song, Siyang, et al.
Publicado: (2022)

Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin
por: Wu, Huan-Huan, et al.
Publicado: (2022)

Trimethoprim-Sulfamethoxazole-induced Hepatotoxicity in a Renal Transplant Patient
por: Slim, R., et al.
Publicado: (2017)

401. Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients After a 6-Month Trimethoprim–Sulfamethoxazole Prophylaxis: A Case–Control Study
por: Park, Se Yoon, et al.
Publicado: (2018)

Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia
por: Kim, Tark, et al.
Publicado: (2018)

Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
por: Koshy, Robin, et al.
Publicado: (2019)

Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial
por: Sohani, Zahra N., et al.
Publicado: (2022)

Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
por: Chapman, Fiona A., et al.
Publicado: (2019)

No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study
por: Huang, Yinqiu, et al.
Publicado: (2022)

Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice
por: Lobo, Maria Luísa, et al.
Publicado: (2013)

Sulfamethoxazole-Trimethoprim and Hyperkalemia in an Infant
por: Hudzik, Samantha A., et al.
Publicado: (2020)

Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Lee, Chang-Hoon
Publicado: (2018)

Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
por: Park, Jun Won, et al.
Publicado: (2018)

A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia
por: Wang, Mengyan, et al.
Publicado: (2019)

Prolonged and recurrent hypoglycemia induced by trimethoprim-sulfamethoxazole in a Hodgkin lymphoma patient with Pneumocystis carinii pneumonia
por: Wang, Bing-Jie, et al.
Publicado: (2021)

Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Kim, Tark, et al.
Publicado: (2018)

Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei
por: Dance, D.A.B., et al.
Publicado: (2014)

An open-label, randomized controlled trial of sulfamethoxazole–trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up
por: Utsunomiya, Masako, et al.
Publicado: (2020)

Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on Severe Pneumocystis Pneumonia After Renal Transplantation
por: Gu, Zhun-Yong, et al.
Publicado: (2022)

Spelling Pneumocystis jirovecii
por: Stringer, James R., et al.
Publicado: (2009)

Etymologia: Pneumocystis jirovecii
por: Henry, Ronnie
Publicado: (2017)

Risk of Pneumocystis jirovecii Pneumonia among Solid Organ Transplant Recipients: A Population-Based Study
por: Cheng, Yih-Dih, et al.
Publicado: (2022)

Analysis of the Clinical Characteristics of Hyponatremia Induced by Trimethoprim/Sulfamethoxazole
por: Lei, Haibo, et al.
Publicado: (2022)

A retrospective study of patients with systemic lupus erythematosus combined with Pneumocystis jiroveci pneumonia treated with caspofungin and trimethoprim/sulfamethoxazole
por: Wang, Zhi-Guo, et al.
Publicado: (2019)

145. the Efficacy and Safety of Low Dose Trimethoprim-sulfamethoxazole for the Treatment of Pneumocystis Pneumonia: A Systematic Review and Meta-analysis
por: Tritle, Brandon, et al.
Publicado: (2020)

Myocarditis after Trimethoprim/Sulfamethoxazole Treatment for Ehrlichiosis
por: Nayak, Seema U., et al.
Publicado: (2013)

Life-Threatening Thrombocytopenia Secondary to Trimethoprim/Sulfamethoxazole
por: Gaudel, Pramod, et al.
Publicado: (2017)

Fixed Drug Eruption to Trimethoprim-Sulfamethoxazole and Doxycycline
por: Long, Clara Y, et al.
Publicado: (2021)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

Antibody Response to Pneumocystis jirovecii: Antibody Response to Pneumocystis jirovecii Major Surface Glycoprotein
por: Daly, Kieran R., et al.
Publicado: (2006)

Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole
por: Park, Jun Won, et al.
Publicado: (2019)

Elizabethkingia Intra-Abdominal Infection and Related Trimethoprim-Sulfamethoxazole Resistance: A Clinical-Genomic Study
por: Teng, Ling-Chiao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_45kb0uc6dro8d4c8ur6dv1tl2o